TP方案联合复方苦参注射液治疗肺癌患者的临床效果及对外周血Foxp3表达的影响

Clinical effect of TP regimen combined with compound Kushen injection for treating lung cancer patients and its influence on peripheral blood Foxp3 expression

目的探讨多西他赛+顺铂(TP)方案联合复方苦参注射液治疗肺癌患者的临床效果及对患者外周血叉头样转录因子3(Foxp3)表达水平的影响。方法选取2018年5月至2020年5月我院收治的肺癌患者96例为观察对象,采用随机数字法分为观察组和对照组,每组48例。在给予常规支持治疗的基础上,对照组患者采用TP方案治疗,观察组患者采用TP方案联合复方苦参注射液治疗,连续治疗4个周期。比较两组患者的临床疗效;比较两组患者治疗前后的临床症状评分;比较两组患者治疗前后的CD4^(+)T细胞、CD4^(+)/CD8^(+)、血清Foxp3表达水平;比较两组患者治疗过程中的不良反应发生情况。结果治疗4个周期,观察组患者的治疗总有效率(68.75%)明显高于对照组(43.75%),差异有统计学意义(P<0.05)。治疗前,两组患者的临床症状评分比较,差异无统计学意义(P>0.05);治疗4个周期后,两组患者的临床症状评分均显著降低,观察组患者的临床症状评分显著低于对照组,差异有统计学意义(P<0.05)。治疗前,两组患者的CD4^(+)T细胞、CD4^(+)/CD8^(+)及Foxp3水平比较,差异无统计学意义(P>0.05)。治疗4个周期后,观察组患者的CD4^(+)T细胞、CD4^(+)/CD8^(+)均显著升高,对照组患者的CD4^(+)T细胞、CD4^(+)/CD8^(+)明显降低,观察组患者的CD4^(+)T细胞、CD4^(+)/CD8^(+)水平显著高于对照组,差异有统计学意义(P<0.05);观察组患者的血清Foxp3表达水平明显降低且显著低于对照组,差异有统计学意义(P<0.05)。治疗过程中,观察组患者腹泻或便秘、恶心呕吐、乏力、血小板减少症的发生率均明显低于对照组,差异有统计学意义(P<0.05)。结论TP方案联合复方苦参注射液治疗肺癌患者临床疗效显著,能显著缓解患者的临床症状,降低患者外周血Foxp3水平,提高患者的免疫功能,减轻化疗药物的毒副作用。

Objective To explore the clinical effect of taxotere+cis-platinum(TP)regimen combined with compound Kushen injection in the treatment of lung cancer patients and the influence on the expression level of peripheral blood Forkhead box protein 3(Foxp3)of patients.Methods A total of 96 lung cancer patients admitted to our hospital from May 2018 to May 2020 were selected as the observation objects,and they were divided into observation group and control group by the random number method,with 48 cases in each group.On the basis of routine supportive treatment,patients in the control group were treated with TP regimen,while the observation group was treated with TP regimen combined with compound Kushen injection for 4 consecutive cycles of treatment.The clinical effects of the two groups were compared.The clinical symptom scores,CD4^(+) T cells,CD4^(+)/CD8^(+) and serum Foxp3 expression levels were compared between the two groups before and after treatment.And the occurrence of adverse reactions during treatment were compared between the two groups.Results After 4 cycles of treatment,the total effective rate of the patients in the observation group(68.75%)was significantly higher than that in the control group(43.75%),with a statistically significant difference(P<0.05).Before treatment,there were no statistically significant differences in clinical symptom scores between the two groups(P>0.05).After 4 cycles of treatment,the scores of clinical symptoms in both groups significantly decreased,which were significantly lower in the observation group than in the control group,with statistically significant difference(P<0.05).Before treatment,there were no statistically significant differences in the levels of CD4^(+) T cells,CD4^(+)/CD8^(+) and Foxp3 between both groups(P>0.05).After 4 cycles of treatment,CD4^(+) T cells and CD4^(+)/CD8^(+) significantly increased in the observation group,whereas significantly decreased in the control group.The levels of CD4^(+) T cells and CD4^(+)/CD8^(+) in the observation group were significantly higher than those in the control group,with statistically significant differences(P<0.05).And the expression level of serum Foxp3 in the observation group significantly decreased,far lower than that in the control group,with a statistically significant difference(P<0.05).During the treatment,the incidence of diarrhea or constipation,nausea and vomiting,asthenia and thrombocytopenia in the observation group were significantly lower than those in the control group,with statistically significant differences(P<0.05).Conclusion TP regimen combined with compound Kushen injection has significant clinical efficacy in the treatment of lung cancer patients,which can significantly alleviate the clinical symptoms,decrease the level of peripheral blood Foxp3,improve the immune function of patients,and reduce the toxic and side effects of chemotherapeutics.